Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Because of their initially low levels of mental functioning, Down syndrome persons' clinical symptoms frequently go undetected until the disease is advanced and deterioration severe.
Why it matters
This paper notes that people with Down syndrome who live past 40 develop the brain pathology of Alzheimer disease, and it presents a preliminary test for assessing regression. It does not report any treatment or cure.
-
Anti-amyloid treatment (AAT) with monoclonal antibodies represents a major therapeutic advance in early Alzheimer disease (AD), but its introduction has important and underappreciated implications for vascular neurology.
Why it matters
Anti-amyloid treatment with monoclonal antibodies is a major therapeutic advance in early Alzheimer disease but has important implications for vascular neurology, since many patients also have cerebral amyloid angiopathy and other cerebrovascular pathology. ARIA, particularly vasogenic edema and microhemorrhages, can mimic acute ischemic stroke and complicate emergency decisions, and reports of intracerebral hemorrhage after intravenous thrombolysis in treated patients point to the need for revised acute stroke pathways.
-
These findings suggest that sexual differentiation in early life has modest effects on adult development of AD in females, a relationship that appeared stronger in the context of APOE4 .
Why it matters
In a mouse model, both female sex and the APOE4 genotype were linked to more β-amyloid pathology, and experimental masculinization had modest effects on some Alzheimer-related outcomes. Because this is an animal study, the results cannot be directly applied to people.
-
To evaluate plasma p-tau217 ability to detect pre-symptomatic Alzheimer disease (AD) in ethnoracially diverse cognitively normal individuals.
Why it matters
This entry only states the objective of evaluating plasma p-tau217 for detecting pre-symptomatic Alzheimer's disease in ethnoracially diverse cognitively normal individuals. No results or conclusions are provided, so no impact on treating, curing or preventing Alzheimer's can be stated.
-
Among 15,346 White, 829 Latino, 637 Black/African American, and 321 Asian individuals, 51% were female, mean age was 75.7 years, 535 (3.8%) resided in ADI 91 to 100 decile, and 61.6% were amyloid PET positive.
Why it matters
People with cognitive impairment living in the most disadvantaged neighborhoods were less likely to have a positive amyloid PET scan by visual reading, though the result was not significant using a different amyloid measure. This suggests neighborhood disadvantage may be linked to lower amyloid pathology in this group.
-
Our findings reinforce the notion of a bidirectional association between epilepsy and AD, providing proof-of-concept that epilepsy, especially late-onset, may be successfully integrated into AD risk frameworks.
Why it matters
This study found a bidirectional association between epilepsy and Alzheimer's disease, with higher risk of Alzheimer's disease in people with epilepsy and much higher risk of epilepsy in people with Alzheimer's disease. It suggests that epilepsy and Alzheimer's disease are linked, but it does not show that treating epilepsy prevents Alzheimer's disease or vice versa.
-
Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction, neuroinflammation, and cognitive impairment.
Why it matters
This review examines how disrupted lipid processing in brain cells contributes to Alzheimer's and proposes lipid dysregulation as a complementary target alongside amyloid- and tau-directed therapies. It is a synthesis of existing data, not a clinical trial, so no treatment benefit is established.
-
Older adults with MDD were more likely to endorse MBI.
Why it matters
This study found that older adults with major depressive disorder were more likely to have mild behavioral impairment, and certain Alzheimer's blood biomarkers were linked to that impairment only in those with depression. It suggests early identification of depression may help manage symptoms, but it does not test a treatment or cure.
-
In the pivotal study in the overall population, the treatment showed a difference of −0.45 points between lecanemab and placebo in the adjusted mean change from baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 18 months (the primary endpoint).
Why it matters
In the pivotal study, lecanemab differed from placebo by −0.45 points on the CDR-SB at 18 months, and ARIA occurred more often in treated patients, including ARIA-E in 12.6% versus 1.7% on placebo. As these antibodies move into practice, the main question shifts from efficacy to how to implement the required risk management measures, which pose logistical challenges that vary by clinical setting.
-
Alzheimer's disease (AD) is a progressive and complicated neurodegenerative disorder that mostly affects the elderly and is characterized by memory loss, cognitive dysfunction, accumulation of amyloid beta (Aβ) plaques, neurofibrillary tangles, and cholinergic deficits.
Why it matters
This review describes the role of BACE1 in generating Aβ peptides and the development of three generations of BACE1 inhibitors, noting that second-generation drugs failed in clinical trials due to adverse effects. It discusses third-generation compounds designed to balance efficacy, selectivity and safety, but no BACE1 inhibitor is presented as an established treatment for Alzheimer's disease.
-
In the study scenario, adding plasma p -tau217 testing to SCE reduced diagnostic costs by $342/patient, through more efficient use of amyloid PET and CSF testing.
Why it matters
Adding plasma p-tau217 testing to standard cognitive evaluation reduced diagnostic costs by $342 per patient through more efficient use of amyloid PET and CSF testing, and was cost-effective at $17,571 per quality-adjusted life year gained. The authors conclude this offers a cost-effective way to support Alzheimer's diagnosis.
-
In Part 1 (currently ongoing), between February 6, 2024, and December 27, 2024, 322 adults were screened, of whom 75 (aged 59-89 years) met NIA-AA and IPA criteria.
Why it matters
This ongoing study presents plasma biomarker data in people with Alzheimer's disease psychosis, and notes that 23 participants met clinical criteria for the condition but were not positive on amyloid tests. The results are intended to inform future clinical trial design, not to treat or prevent the disease.
-
Our findings highlight the potential of diverse genomic backgrounds to uncover protective genetic factors, such as the African-specific protective PSG2 locus, found to confer a protective effect among APOE4 carriers.
Why it matters
Diverse genomic backgrounds can uncover protective genetic factors, such as the African-specific PSG2 locus that confers protection among APOE4 carriers. This highlights the potential of African ancestry diversity for global advances in Alzheimer's genetics.
-
During alteplase administration, the patient experienced clinical deterioration.
Why it matters
This case report describes a person with Down syndrome and Alzheimer's disease who had a brain hemorrhage after stroke treatment, with evidence of cerebral amyloid angiopathy. It highlights that there is no established guidance for managing this combination, and more data are needed.
-
The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task.
Why it matters
Using quantitative EEG during dual-task paradigms, this study found brain signal differences between carriers and non-carriers of the PSEN1-E280A variant in preclinical stages. It suggests these measures could enhance non-invasive tools for identifying carriers, but it does not test any treatment, cure or prevention.
-
The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task.
Why it matters
Using quantitative EEG during dual-task paradigms, this study found brain signal differences between carriers and non-carriers of the PSEN1-E280A variant in preclinical stages. It suggests these measures could enhance non-invasive tools for identifying carriers, but it does not test any treatment, cure or prevention.
-
Both patient groups showed significant deviations from HC, but with distinct patterns.
Why it matters
Resting-state EEG showed different patterns of brain activity in Alzheimer's disease versus frontotemporal dementia, and these patterns were stable across eye-open and eye-closed states. This supports EEG as a possible low-cost, non-invasive extra tool to help tell these two dementias apart, though it is not a treatment.
-
Cerebral amyloid angiopathy (CAA), which is prevalent among older adults, constitutes a major cause of brain hemorrhage, dementia, and cognitive decline.
Why it matters
Using Mendelian randomization on druggable genes, this study identified 10 genes significantly associated with cerebral amyloid angiopathy risk and found that DPP9 shares a causal genetic variant with CAA. It is a genetic drug-target discovery study and no treatment, cure or prevention is tested in patients.
-
Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive memory loss and cognitive decline.
Why it matters
This review discusses how molecular dynamics simulations are used to study natural compounds that might block amyloid-beta aggregation, based on the idea that amyloid-beta clumping starts the disease process. It is a computational and review-based work, so it does not show that any compound prevents or treats Alzheimer's in people.
-
Alzheimer's disease (AD), the most common form of dementia, is characterized by progressive cognitive decline and neuropathological hallmarks, including amyloid-beta plaques and tau tangles.
Why it matters
This review discusses metabolic problems such as impaired glucose metabolism, insulin resistance and mitochondrial dysfunction in Alzheimer's disease, and notes that insulin sensitizers, ketogenic diets and mitochondrial-targeted antioxidants have shown promise in preclinical and early clinical studies. It does not report a proven treatment or cure.
-
BackgroundAlzheimer's disease (AD) exhibits significant clinical and pathological heterogeneity, particularly during the mild cognitive impairment (MCI) transitional stage.
Why it matters
This study found two distinct molecular subtypes of progression from mild cognitive impairment to Alzheimer's disease: one with metabolic dysregulation and slower decline, and another with chronic immune activation and faster decline. These findings could help personalize interventions, but no treatment or cure is tested.
-
The APOE (apolipoprotein E) ε4 allele is the strongest known genetic risk factor for sporadic Alzheimer disease (AD) and for brain amyloidosis, an early marker of disease pathophysiology.
Why it matters
This study proposes that studying people who carry only the APOE ε3 form of the gene may reveal new genetic predictors of brain amyloid buildup. It has not yet reported any new predictors; it describes the rationale for a planned analysis.
-
We found that orientation, memory, and irritability scores were useful in predicting AD dementia onset, while daily living, depression, and executive function scores were identified as strong predictors in the LB cohort.
Why it matters
This study found that different cognitive and neuropsychiatric domains predicted conversion to dementia in patients with Alzheimer's disease versus Lewy body pathology. It is about predicting progression and does not test any treatment, cure, or prevention.
-
Fifty-four participants (~8% response rate) from the MindCrowd web-based cohort (mean age of 62.39 years; 39 females; and 23 APOE ε4 carriers) completed 75 trials of Super G. Results show that Super G performance was significantly associated with each of the targeted risk factors.
Why it matters
In 54 participants from the MindCrowd web cohort, performance on a digital motor skill game was associated with Alzheimer's risk factors, including slower response time in APOE ε4 carriers. This is a small cross-sectional study, and the authors describe the game as having potential as a screening biomarker, not as a treatment or prevention.
-
This report highlights a case of relapsing remitting rapidly progressive dementia due to cerebral amyloid angiopathy-related inflammation (CAA-ri), focusing on the diagnostic challenges and the dramatic response to corticosteroid treatment.
Why it matters
This case report describes a patient with relapsing remitting rapidly progressive dementia due to cerebral amyloid angiopathy-related inflammation, highlighting the difficulty of diagnosis. The patient had a dramatic response to corticosteroid treatment.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation
- The effects of donepezil in Alzheimer's disease - results from a multinational trial
- Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
- Alzheimer's disease in Down's syndrome: clinicopathologic studies
- Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease
- Prion disease mimicking rapidly progressive Alzheimer disease: case series and systematic review
- Multimodal Deep Learning for Dynamic and Static Neuroimaging: Integrating MRI and fMRI for Alzheimer Disease Analysis
- CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis
- Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
- A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss